PROTALIX BIOTHERAPEUTICS, INC. (PLX) scores 49 out of 100 on boothcheck's 11-model valuation framework. Verdict: Poor The estimated fair value is 2.58, representing a 16% margin of safety. Quantitative score: 51/100. Qualitative score: 60/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.